Stratec SE (ETR: SBS)
Market Cap | 418.16M |
Revenue (ttm) | 250.54M |
Net Income (ttm) | 10.01M |
Shares Out | 12.16M |
EPS (ttm) | 0.82 |
PE Ratio | 41.95 |
Forward PE | 21.93 |
Dividend | 0.55 (1.71%) |
Ex-Dividend Date | May 20, 2024 |
Volume | 13,187 |
Average Volume | 9,889 |
Open | 31.85 |
Previous Close | 32.10 |
Day's Range | 31.85 - 35.15 |
52-Week Range | 26.05 - 48.60 |
Beta | 0.27 |
RSI | 64.86 |
Earnings Date | Mar 27, 2025 |
About Stratec SE
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headqu... [Read more]
Financial Performance
In 2023, Stratec SE's revenue was 261.91 million, a decrease of -4.63% compared to the previous year's 274.63 million. Earnings were 13.07 million, a decrease of -55.29%.
Financial StatementsNews
EQS-News: STRATEC TO PARTICIPATE IN THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
EQS-News: STRATEC SE / Key word(s): Conference STRATEC TO PARTICIPATE IN THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 08.01.2025 / 15:18 CET/CEST The issuer is solely responsible for the content ...
STRATEC Unveils Impressive Results for First 9 Months of 2024
STRATEC faced a challenging first nine months of 2024, with sales dipping by 6.1% amid a strategic workforce reduction. However, the company remains optimistic about a rebound in Q4. Jetzt den vollstä...
EQS-News: STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2024
EQS-News: STRATEC SE / Key word(s): Quarter Results STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2024 25.10.2024 / 06:55 CET/CEST The issuer is solely responsible for the content of this announcem...
STRATEC Confirms EBIT Margin, Adjusts 2024 Sales Guidance in Q3 Results
STRATEC faced a dip in sales in the first nine months of 2024, yet maintained solid profitability. With postponed deliveries and new orders on the horizon, the company anticipates a rebound in Q4. Jet...
EQS-Adhoc: STRATEC POSTS PRELIMINARY RESULTS FOR FIRST NINE MONTHS OF 2024: TARGET CORRIDOR FOR ADJUSTED EBIT MARGIN CONFIRMED WITH ADJUSTMENT TO 2024 SALES GUIDANCE
EQS-Ad-hoc: STRATEC SE / Key word(s): Preliminary Results/Change in Forecast STRATEC POSTS PRELIMINARY RESULTS FOR FIRST NINE MONTHS OF 2024: TARGET CORRIDOR FOR ADJUSTED EBIT MARGIN CONFIRMED WITH AD...
STRATEC's H1 2024 Results: Key Insights and Performance Highlights
STRATEC faced a 4.9% sales dip in H1 2024, yet saw an improved EBIT margin and promising Q2 growth. Despite a smaller workforce, the company remains optimistic about its future market launches and 202...
EQS-News: STRATEC POSTS RESULTS FOR FIRST HALF OF 2024
EQS-News: STRATEC SE / Key word(s): Half Year Results/Half Year Report STRATEC POSTS RESULTS FOR FIRST HALF OF 2024 09.08.2024 / 06:55 CET/CEST The issuer is solely responsible for the content of this...